Review



mesothelioma  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals mesothelioma
    Representative immunofluorescent staining of cultured <t>mesothelioma</t> cells using AX10 antibody (a), immunohistochemical staining (b), and secondary antibody‐drug conjugate assay in vitro (c). (a) AX10 immunoreactivity in MPM‐1, −2, and −3 cells, representing sarcomatoid, epithelioid, and biphasic type mesothelioma, respectively. All MPM‐1, −2, and −3 cells exhibited AX10 antibody immunoreactivity at the cell surface. The staining was analyzed using a Guava easyCyte cell analyzer and accompanying software to obtain a one‐parameter log histogram. (b) AX10 immunoreactivity in various mesothelioma tissue specimens. Weak or no AX10 immunoreactivity was detected in five out of 10 epithelioid mesothelioma tissues (a). One out of five biphasic mesotheliomas exhibited AX10 immunoreactivity in spindle sarcomatoid components (arrow) but weak immunoreactivity in epithelioid components (arrowhead) (b). Five out of six sarcomatoid mesothelioma tissues exhibited strong AX10 immunoreactivity (c). Little AX10 immunoreactivity was detected in normal human tissues. No significant AX10 immunoreactivity was detected in the lung (d) (pleural mesothelial cells; insert) tissue specimens. Weak AX10 immunoreactivity was detected in myofibrous cells in the uterus (e). We did not detect any significant AX10 immunoreactivity in the brain, liver, or kidney, whereas strong AX10 immunoreactivity was observed in a nonmelanocytic (hypomelanocytic) melanoma tissue sample that was supplementally included in the microarray (f) (staining without AX10 antibody; insert). (c) MPM‐1 sarcomatoid mesothelioma cells were incubated with AX10 at 10, 100, and 1000 ng/mL followed by incubation with anti‐murine IgG (Fc) antibody conjugated to duocarmycin. Representative staining with Annexin V‐PI is presented. Note the dose‐dependent Annexin V‐positive and PI‐negative apoptotic MPM‐1 cells in the presence of AX10 antibody
    Mesothelioma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/Human+FDA+Standard+Tissue+MicroArray+(Normal)/pmc09475231-47-4-27
    Average 93 stars, based on 2 article reviews
    mesothelioma - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells"

    Article Title: Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells

    Journal: Thoracic Cancer

    doi: 10.1111/1759-7714.14591

    Representative immunofluorescent staining of cultured mesothelioma cells using AX10 antibody (a), immunohistochemical staining (b), and secondary antibody‐drug conjugate assay in vitro (c). (a) AX10 immunoreactivity in MPM‐1, −2, and −3 cells, representing sarcomatoid, epithelioid, and biphasic type mesothelioma, respectively. All MPM‐1, −2, and −3 cells exhibited AX10 antibody immunoreactivity at the cell surface. The staining was analyzed using a Guava easyCyte cell analyzer and accompanying software to obtain a one‐parameter log histogram. (b) AX10 immunoreactivity in various mesothelioma tissue specimens. Weak or no AX10 immunoreactivity was detected in five out of 10 epithelioid mesothelioma tissues (a). One out of five biphasic mesotheliomas exhibited AX10 immunoreactivity in spindle sarcomatoid components (arrow) but weak immunoreactivity in epithelioid components (arrowhead) (b). Five out of six sarcomatoid mesothelioma tissues exhibited strong AX10 immunoreactivity (c). Little AX10 immunoreactivity was detected in normal human tissues. No significant AX10 immunoreactivity was detected in the lung (d) (pleural mesothelial cells; insert) tissue specimens. Weak AX10 immunoreactivity was detected in myofibrous cells in the uterus (e). We did not detect any significant AX10 immunoreactivity in the brain, liver, or kidney, whereas strong AX10 immunoreactivity was observed in a nonmelanocytic (hypomelanocytic) melanoma tissue sample that was supplementally included in the microarray (f) (staining without AX10 antibody; insert). (c) MPM‐1 sarcomatoid mesothelioma cells were incubated with AX10 at 10, 100, and 1000 ng/mL followed by incubation with anti‐murine IgG (Fc) antibody conjugated to duocarmycin. Representative staining with Annexin V‐PI is presented. Note the dose‐dependent Annexin V‐positive and PI‐negative apoptotic MPM‐1 cells in the presence of AX10 antibody
    Figure Legend Snippet: Representative immunofluorescent staining of cultured mesothelioma cells using AX10 antibody (a), immunohistochemical staining (b), and secondary antibody‐drug conjugate assay in vitro (c). (a) AX10 immunoreactivity in MPM‐1, −2, and −3 cells, representing sarcomatoid, epithelioid, and biphasic type mesothelioma, respectively. All MPM‐1, −2, and −3 cells exhibited AX10 antibody immunoreactivity at the cell surface. The staining was analyzed using a Guava easyCyte cell analyzer and accompanying software to obtain a one‐parameter log histogram. (b) AX10 immunoreactivity in various mesothelioma tissue specimens. Weak or no AX10 immunoreactivity was detected in five out of 10 epithelioid mesothelioma tissues (a). One out of five biphasic mesotheliomas exhibited AX10 immunoreactivity in spindle sarcomatoid components (arrow) but weak immunoreactivity in epithelioid components (arrowhead) (b). Five out of six sarcomatoid mesothelioma tissues exhibited strong AX10 immunoreactivity (c). Little AX10 immunoreactivity was detected in normal human tissues. No significant AX10 immunoreactivity was detected in the lung (d) (pleural mesothelial cells; insert) tissue specimens. Weak AX10 immunoreactivity was detected in myofibrous cells in the uterus (e). We did not detect any significant AX10 immunoreactivity in the brain, liver, or kidney, whereas strong AX10 immunoreactivity was observed in a nonmelanocytic (hypomelanocytic) melanoma tissue sample that was supplementally included in the microarray (f) (staining without AX10 antibody; insert). (c) MPM‐1 sarcomatoid mesothelioma cells were incubated with AX10 at 10, 100, and 1000 ng/mL followed by incubation with anti‐murine IgG (Fc) antibody conjugated to duocarmycin. Representative staining with Annexin V‐PI is presented. Note the dose‐dependent Annexin V‐positive and PI‐negative apoptotic MPM‐1 cells in the presence of AX10 antibody

    Techniques Used: Staining, Cell Culture, Immunohistochemical staining, In Vitro, Software, Microarray, Incubation

    AX10 does not affect cell proliferation, but significantly decreases Matrigel invasion activity of MPM‐1 sarcomatoid mesothelioma cells in vitro. (a) Representative cell proliferation assay. At 24 h, the cell number was 1.80 ± 0.10 (mock) and 1.77 ± 0.06 (AX10). Respective numbers at 48 h were 2.40 ± 0.10 (mock) and 2.37 ± 0.12 (AX10), while at 72 h they were 3.90 ± 0.20 (mock) and 4.20 ± 0.61 (AX10). The data represent means ± SD from triplicate assays (Student's t ‐test, p > 0.5). (b) AX10 significantly reduced Matrigel invasion activity of MPM‐1 cells (Student's t ‐test, p < 0.01). The number of invading cells was 59.7 ± 7.02 (mock) and 10.3 ± 1.52 (AX10) at 24 h, and 210.7 ± 11.4 (mock) and 15.0 ± 3.00 (AX10) at 48 h. Data from triplicate assays are expressed as means ± SD ( n = 3). (c) Cells that migrated to the lower surface of the membrane are shown (48 h). Original magnification, ×100
    Figure Legend Snippet: AX10 does not affect cell proliferation, but significantly decreases Matrigel invasion activity of MPM‐1 sarcomatoid mesothelioma cells in vitro. (a) Representative cell proliferation assay. At 24 h, the cell number was 1.80 ± 0.10 (mock) and 1.77 ± 0.06 (AX10). Respective numbers at 48 h were 2.40 ± 0.10 (mock) and 2.37 ± 0.12 (AX10), while at 72 h they were 3.90 ± 0.20 (mock) and 4.20 ± 0.61 (AX10). The data represent means ± SD from triplicate assays (Student's t ‐test, p > 0.5). (b) AX10 significantly reduced Matrigel invasion activity of MPM‐1 cells (Student's t ‐test, p < 0.01). The number of invading cells was 59.7 ± 7.02 (mock) and 10.3 ± 1.52 (AX10) at 24 h, and 210.7 ± 11.4 (mock) and 15.0 ± 3.00 (AX10) at 48 h. Data from triplicate assays are expressed as means ± SD ( n = 3). (c) Cells that migrated to the lower surface of the membrane are shown (48 h). Original magnification, ×100

    Techniques Used: Activity Assay, In Vitro, Proliferation Assay, Membrane

    Inhibitory effect of AX10 on MPM‐1 xenotransplanted sarcomatoid mesothelioma cell proliferation. (a) Inoculation of AX10 antibody delayed the growth of xenotransplanted MPM‐1 sarcomatoid mesothelioma tumors. On day 0, SCID‐NOD mice were subcutaneously implanted with MPM‐1 cells. The following day, day 3, the mice were administered AX10 antibody or vehicle only by intraperitoneal injection and weekly thereafter as indicated by arrows. Values are represented as means ± standard error for n = 5 mice. Statistical significance was measured by a two‐sided unpaired Student's t ‐test (* p < 0.01). (b) On day 42, the xenotransplanted tumors were excised to determine their weight. Total tumor weights are represented as means ± standard error for n = 5 mice. Statistical significance was measured by a two‐sided unpaired Student's t ‐test ( p < 0.01). (c) Gross and histological appearance of a representative xenotransplanted tumor. Arrowhead indicates the tumor without AX10 antibody, while the arrow indicates the small tumor remaining following weekly AX10 injection. Note the elimination of tumor cells, which were histologically replaced by regenerative muscle in mice inoculated with AX10 antibody. Scale bar indicates 100 μm
    Figure Legend Snippet: Inhibitory effect of AX10 on MPM‐1 xenotransplanted sarcomatoid mesothelioma cell proliferation. (a) Inoculation of AX10 antibody delayed the growth of xenotransplanted MPM‐1 sarcomatoid mesothelioma tumors. On day 0, SCID‐NOD mice were subcutaneously implanted with MPM‐1 cells. The following day, day 3, the mice were administered AX10 antibody or vehicle only by intraperitoneal injection and weekly thereafter as indicated by arrows. Values are represented as means ± standard error for n = 5 mice. Statistical significance was measured by a two‐sided unpaired Student's t ‐test (* p < 0.01). (b) On day 42, the xenotransplanted tumors were excised to determine their weight. Total tumor weights are represented as means ± standard error for n = 5 mice. Statistical significance was measured by a two‐sided unpaired Student's t ‐test ( p < 0.01). (c) Gross and histological appearance of a representative xenotransplanted tumor. Arrowhead indicates the tumor without AX10 antibody, while the arrow indicates the small tumor remaining following weekly AX10 injection. Note the elimination of tumor cells, which were histologically replaced by regenerative muscle in mice inoculated with AX10 antibody. Scale bar indicates 100 μm

    Techniques Used: Injection

    Related Articles

    Food & Beverages:

    Article Title: Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells
    Article Snippet: After further washing with PBS, the cells were analyzed using a Guava easyCyte cell analyzer (Guava Technologies, Inc.). .. Tissue microarrays composed of mesothelioma (Cat. No. MS801b) and Food and Drug Administration (FDA) normal organ tissue arrays (Cat. No. NBP2‐78057) were purchased from US Biomax and Novus Biologicals, respectively. .. A universal IHC/ISH control tissue array was purchased from Pantomics, Inc. All tissue samples were collected according to ethical standards and the Health Insurance Portability and Accountability Act (USA).



    Similar Products

    oxyferm fda vp 120  (Hamilton Company)
    98
    Hamilton Company oxyferm fda vp 120
    Oxyferm Fda Vp 120, supplied by Hamilton Company, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/OxyFerm+FDA+VP+120/custom%40237540%4010%2E1016%2Fj%2Ecej%2E2026%2E179749
    Average 98 stars, based on 1 article reviews
    oxyferm fda vp 120 - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    tocriscreen fda-approved drugs library  (Bio-Techne corporation)
    93
    Bio-Techne corporation tocriscreen fda-approved drugs library
    Tocriscreen Fda Approved Drugs Library, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/Tocriscreen+FDA-Approved+Drugs+Library/custom%407200%4042085862
    Average 93 stars, based on 1 article reviews
    tocriscreen fda-approved drugs library - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    fda  (Mendeley Ltd)
    86
    Mendeley Ltd fda
    Fda, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/approved+fda/pm41949508-340-3-37
    Average 86 stars, based on 1 article reviews
    fda - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    fda-approved saliva collection kit  (Color Genomics)
    90
    Color Genomics fda-approved saliva collection kit
    Fda Approved Saliva Collection Kit, supplied by Color Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/fda+approved+saliva+collection+kit/nct03762590-17-5-10
    Average 90 stars, based on 1 article reviews
    fda-approved saliva collection kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    simplexa hsv 1 & 2 direct  (DiaSorin Biotechnology)
    96
    DiaSorin Biotechnology simplexa hsv 1 & 2 direct
    Simplexa Hsv 1 & 2 Direct, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/Simplexa+HSV+1+%26+2+Direct/custom%40mol2150%4042378730
    Average 96 stars, based on 1 article reviews
    simplexa hsv 1 & 2 direct - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    prestwick fda approved drug library  (Prestwick Chemical)
    86
    Prestwick Chemical prestwick fda approved drug library
    High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) <t>Prestwick</t> <t>FDA</t> (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.
    Prestwick Fda Approved Drug Library, supplied by Prestwick Chemical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/1280+approved+compounds+fda/pmc13207355-27-0-6
    Average 86 stars, based on 1 article reviews
    prestwick fda approved drug library - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    prestwick fda  (Prestwick Chemical)
    86
    Prestwick Chemical prestwick fda
    High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) <t>Prestwick</t> <t>FDA</t> (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.
    Prestwick Fda, supplied by Prestwick Chemical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/fda+prestwick/pmc13207355-2-0-5
    Average 86 stars, based on 1 article reviews
    prestwick fda - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    fda  (Accelerate Diagnostics)
    86
    Accelerate Diagnostics fda
    High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) <t>Prestwick</t> <t>FDA</t> (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.
    Fda, supplied by Accelerate Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/us12655460-133-9-10
    Average 86 stars, based on 1 article reviews
    fda - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    fluorescein diacetate fda  (Yeasen Biotechnology)
    86
    Yeasen Biotechnology fluorescein diacetate fda
    High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) <t>Prestwick</t> <t>FDA</t> (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.
    Fluorescein Diacetate Fda, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fda/diacetate+fluorescein/pm42283233-31-0-12
    Average 86 stars, based on 1 article reviews
    fluorescein diacetate fda - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) Prestwick FDA (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.

    Journal: iScience

    Article Title: A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models

    doi: 10.1016/j.isci.2026.115839

    Figure Lengend Snippet: High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) Prestwick FDA (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.

    Article Snippet: Prestwick FDA approved Drug Library , Prestwick Chemical , https://www.prestwickchemical.com/screening-libraries/prestwick-chemical-library/.

    Techniques: Drug discovery, High Content Screening, Plasmid Preparation, Labeling

    High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) Prestwick FDA (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.

    Journal: iScience

    Article Title: A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models

    doi: 10.1016/j.isci.2026.115839

    Figure Lengend Snippet: High-content image analysis/dimensionality reduction of drug screening data (A–C) Representative data of high content analysis across six GSC lines and three compound libraries (LOPAC, (A) Prestwick FDA (B) and C3L, (C) by 3D principal component analysis (PCA) (median aggregation to well level, n = 6 fields of view). DMSO controls circled in Black ( n = 48 per plate). Magnitude of vector co-ordinates for PC1, 2, 3 (sized by PC4) are indicated by color, red-pink (strong –PC1, –PC2), blue (strong +PC3, –PC2), green (strong +PC1 +PC2), yellow/gray (weaker phenotypes). PC1-4 factor loadings are given (%). Factor loadings are provided in . (D–F) Phenotypic distance of screened compounds (LOPAC, D, Prestwick FDA, E and C3L, F). We employed 20 principal components (>60% explained variance) to compute a phenotypic distance (Euclidean) for each compound. The corresponding p values are plotted against cell survival (normalized z scores, y axis). Legend indicates strength of –log 10 [ p value] distribution (five bins, red = maximal effect, reducing to gray where at = arbitrary threshold). Several example hits are labeled.

    Article Snippet: Prestwick FDA , 1,280 , Prestwick Chemical (∼2016) https://www.prestwickchemical.com/screening-libraries/prestwick-chemical-library/ , 10,000, 1,000 , Staurosporine (1,000 nM).

    Techniques: Drug discovery, High Content Screening, Plasmid Preparation, Labeling